- Home
- UNCY vs HUMA Comparison
UNCY vs HUMA Comparison
Compare UNCY & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UNCY | HUMA |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1M | 165.7M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UNCY | HUMA |
|---|---|---|
| Price | $4.59 | $0.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $29.60 | $1.85 |
| AVG Volume (30 Days) | 767.1K | ★ 2.9M |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.37 |
| EPS | N/A | ★ N/A |
| Revenue | $675,000.00 | ★ $2,038,000.00 |
| Revenue This Year | N/A | $72.32 |
| Revenue Next Year | $52,701.90 | $518.79 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.93 | $0.53 |
| 52 Week High | $8.74 | $2.55 |
Technical Indicators
Market Signals| Indicator | UNCY | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 40.81 | 34.26 |
| Support Level | $3.93 | N/A |
| Resistance Level | $5.86 | $0.61 |
| Average True Range (ATR) | 0.20 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 38.32 | 9.05 |
Price Performance
Historical ComparisonAbout UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
About HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.